Literature DB >> 28102754

Enhancement of antibody functions through Fc multiplications.

Qun Wang1, Yan Chen2, Mark Pelletier1, Romana Cvitkovic1, Jessica Bonnell1, Chien-Ying Chang2, Adem C Koksal2, Ellen O'Connor3, Xizhe Gao4, Xiang-Qing Yu4, Herren Wu2, C Kendall Stover1, William F Dall'Acqua2, Xiaodong Xiao2.   

Abstract

Antibodies carry out a plethora of functions through their crystallizable fragment (Fc) regions, which can be naturally tuned by the adoption of several isotypes and post-translational modifications. Protein engineering enables further Fc function modulations through modifications of the interactions between the Fc and its functional partners, including FcγR, FcRn, complement complex, and additions of auxiliary functional units. Due to the many functions embedded within the confinement of an Fc, a suitable balance must be maintained for a therapeutic antibody to be effective and safe. The outcome of any Fc engineering depends on the interplay among all the effector molecules involved. In this report, we assessed the effects of Fc multiplication (or tandem Fc) on antibody functions. Using IgG1 as a test case, we found that, depending on the specifically designed linker, Fc multiplication led to differentially folded, stable molecules with unique pharmacokinetic profiles. Interestingly, the variants with 3 copies of Fc improved in vitro opsonophagocytic killing activity and displayed significantly improved protective efficacies in a Klebsiella pneumoniae mouse therapeutic model despite faster clearance compared with its IgG1 counterpart. There was no adverse effect observed or pro-inflammatory cytokine release when the Fc variants were administered to animals. We further elucidated that enhanced binding to various effector molecules by IgG-3Fc created a "sink" leading to the rapid clearance of the 3Fc variants, and identified the increased FcRn binding as one strategy to facilitate "sink" escape. These findings reveal new opportunities for novel Fc engineering to further expand our abilities to manipulate and improve antibody therapeutics.

Entities:  

Keywords:  Effector function; opsonophagocytic killing (OPK); pharmacokinetics (PK); serum clearance; tandem Fc

Mesh:

Substances:

Year:  2017        PMID: 28102754      PMCID: PMC5384704          DOI: 10.1080/19420862.2017.1281505

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  31 in total

1.  TNF receptor II fusion protein with tandemly repeated Fc domains.

Authors:  Hiroaki Nagashima; Kaname Kaneko; Ayaka Yamanoi; Sotaro Motoi; Shu Konakahara; Junya Kohroki; Yasuhiko Masuho
Journal:  J Biochem       Date:  2011-01-28       Impact factor: 3.387

2.  Enhanced antibody-dependent cellular phagocytosis by chimeric monoclonal antibodies with tandemly repeated Fc domains.

Authors:  Hiroaki Nagashima; Michiko Ootsubo; Mizuki Fukazawa; Sotaro Motoi; Shu Konakahara; Yasuhiko Masuho
Journal:  J Biosci Bioeng       Date:  2011-01-06       Impact factor: 2.894

3.  Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading.

Authors:  Pavel Strop; Kathy Delaria; Davide Foletti; Jody Melton Witt; Adela Hasa-Moreno; Kris Poulsen; Meritxell Galindo Casas; Magdalena Dorywalska; Santiago Farias; Ariel Pios; Victor Lui; Russell Dushin; Dahui Zhou; Thayalan Navaratnam; Thomas-Toan Tran; Janette Sutton; Kevin C Lindquist; Bora Han; Shu-Hui Liu; David L Shelton; Jaume Pons; Arvind Rajpal
Journal:  Nat Biotechnol       Date:  2015-07       Impact factor: 54.908

4.  pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.

Authors:  M Jack Borrok; Yanli Wu; Nurten Beyaz; Xiang-Qing Yu; Vaheh Oganesyan; William F Dall'Acqua; Ping Tsui
Journal:  J Biol Chem       Date:  2014-12-23       Impact factor: 5.157

Review 5.  Harnessing Fc receptor biology in the design of therapeutic antibodies.

Authors:  Peter Sondermann; David E Szymkowski
Journal:  Curr Opin Immunol       Date:  2016-03-30       Impact factor: 7.486

6.  FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.

Authors:  Rony Dahan; Emanuela Sega; John Engelhardt; Mark Selby; Alan J Korman; Jeffrey V Ravetch
Journal:  Cancer Cell       Date:  2015-09-14       Impact factor: 31.743

7.  The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs.

Authors:  Derry C Roopenian; Gregory J Christianson; Thomas J Sproule; Aaron C Brown; Shreeram Akilesh; Nadja Jung; Stefka Petkova; Lia Avanessian; Eun Young Choi; Daniel J Shaffer; Peter A Eden; Clark L Anderson
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

8.  Enhanced antibody half-life improves in vivo activity.

Authors:  Jonathan Zalevsky; Aaron K Chamberlain; Holly M Horton; Sher Karki; Irene W L Leung; Thomas J Sproule; Greg A Lazar; Derry C Roopenian; John R Desjarlais
Journal:  Nat Biotechnol       Date:  2010-01-17       Impact factor: 54.908

9.  The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan.

Authors:  Chaity Chaudhury; Samina Mehnaz; John M Robinson; William L Hayton; Dennis K Pearl; Derry C Roopenian; Clark L Anderson
Journal:  J Exp Med       Date:  2003-02-03       Impact factor: 14.307

10.  Structural characterization of a human Fc fragment engineered for lack of effector functions.

Authors:  Vaheh Oganesyan; Changshou Gao; Lena Shirinian; Herren Wu; William F Dall'Acqua
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2008-05-14
View more
  7 in total

Review 1.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

2.  Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.

Authors:  Dennis R Goulet; Adam Zwolak; James A Williams; Mark L Chiu; William M Atkins
Journal:  Proteins       Date:  2019-11-20

Review 3.  Innate Host Defense against Klebsiella pneumoniae and the Outlook for Development of Immunotherapies.

Authors:  Clement Opoku-Temeng; Natalia Malachowa; Scott D Kobayashi; Frank R DeLeo
Journal:  J Innate Immun       Date:  2021-10-08       Impact factor: 7.111

4.  Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2.

Authors:  Bruce D Wines; Halina M Trist; Sandra Esparon; Rachael E Impey; Graham A Mackay; Robert K Andrews; Tatiana P Soares da Costa; Geoffrey A Pietersz; Ross I Baker; P Mark Hogarth
Journal:  Front Immunol       Date:  2021-10-25       Impact factor: 7.561

5.  In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.

Authors:  Dapeng Li; Robert J Edwards; Kartik Manne; David R Martinez; Alexandra Schäfer; S Munir Alam; Kevin Wiehe; Xiaozhi Lu; Robert Parks; Laura L Sutherland; Thomas H Oguin; Charlene McDanal; Lautaro G Perez; Katayoun Mansouri; Sophie M C Gobeil; Katarzyna Janowska; Victoria Stalls; Megan Kopp; Fangping Cai; Esther Lee; Andrew Foulger; Giovanna E Hernandez; Aja Sanzone; Kedamawit Tilahun; Chuancang Jiang; Longping V Tse; Kevin W Bock; Mahnaz Minai; Bianca M Nagata; Kenneth Cronin; Victoria Gee-Lai; Margaret Deyton; Maggie Barr; Tarra Von Holle; Andrew N Macintyre; Erica Stover; Jared Feldman; Blake M Hauser; Timothy M Caradonna; Trevor D Scobey; Wes Rountree; Yunfei Wang; M Anthony Moody; Derek W Cain; C Todd DeMarco; Thomas N Denny; Christopher W Woods; Elizabeth W Petzold; Aaron G Schmidt; I-Ting Teng; Tongqing Zhou; Peter D Kwong; John R Mascola; Barney S Graham; Ian N Moore; Robert Seder; Hanne Andersen; Mark G Lewis; David C Montefiori; Gregory D Sempowski; Ralph S Baric; Priyamvada Acharya; Barton F Haynes; Kevin O Saunders
Journal:  Cell       Date:  2021-06-18       Impact factor: 66.850

6.  DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity.

Authors:  Claudio Sustmann; Steffen Dickopf; Jörg T Regula; Hubert Kettenberger; Michael Mølhøj; Christian Gassner; Diana Weininger; Sebastian Fenn; Tobias Manigold; Lothar Kling; Klaus-Peter Künkele; Manfred Schwaiger; Birgit Bossenmaier; Julia J Griese; Karl-Peter Hopfner; Alexandra Graff-Meyer; Henning Stahlberg; Philippe Ringler; Matthias E Lauer; Ulrich Brinkmann; Wolfgang Schaefer; Christian Klein
Journal:  MAbs       Date:  2019-09-17       Impact factor: 5.857

Review 7.  In Translation: FcRn across the Therapeutic Spectrum.

Authors:  Timothy Qi; Yanguang Cao
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.